ESPR logo

Esperion Therapeutics (ESPR) Long Term Liabilities

Annual Total Long Term Liabilities

$504.57 M
+$25.16 M+5.25%

31 December 2023

ESPR Long Term Liabilities Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Quarterly Long Term Liabilities

$518.45 M
-$2.75 M-0.53%

30 September 2024

ESPR Quarterly Long Term Liabilities Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

ESPR Long Term Liabilities Performance

PeriodPeriodAnnualAnnualQuarterlyQuarterly
1 y1 year+5.3%+5.0%
3 y3 years+42.0%+1.8%
5 y5 years+100.0%+301.1%

ESPR Long Term Liabilities High & Low

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs low
3 y3 years-0.1%+42.0%-1.2%+8.1%
5 y5 years-0.1%-1.2%+303.7%
alltimeall time-0.1%-1.2%

Esperion Therapeutics Long Term Liabilities History

DateAnnualQuarterly
Sept 2024
-
$518.45 M(-0.5%)
June 2024
-
$521.20 M(+3.7%)
Mar 2024
-
$502.85 M(-0.3%)
Dec 2023
$504.57 M(+5.2%)
$504.57 M(+2.2%)
Sept 2023
-
$493.60 M(-1.2%)
June 2023
-
$499.43 M(+2.8%)
Mar 2023
-
$486.00 M(+1.4%)
Dec 2022
$479.41 M(-5.1%)
$479.41 M(-8.6%)
Sept 2022
-
$524.58 M(+2.2%)
June 2022
-
$513.40 M(+0.1%)
Mar 2022
-
$512.81 M(+1.5%)
Dec 2021
$505.18 M(+42.2%)
$505.18 M(-0.8%)
Sept 2021
-
$509.48 M(+1.5%)
June 2021
-
$502.13 M(+11.6%)
Mar 2021
-
$450.11 M(+26.7%)
Dec 2020
$355.32 M(+176.7%)
$355.32 M(+114.0%)
Sept 2020
-
$166.06 M(+3.2%)
June 2020
-
$160.98 M(+2.9%)
Mar 2020
-
$156.44 M(+21.8%)
Dec 2019
$128.42 M(>+9900.0%)
$128.42 M(-0.6%)
Sept 2019
-
$129.24 M(+3.3%)
June 2019
-
$125.17 M(+8550.2%)
Mar 2019
-
$1.45 M(>+9900.0%)
Dec 2018
$0.00
$0.00(0.0%)
Sept 2018
-
$0.00(0.0%)
June 2018
-
$0.00(0.0%)
DateAnnualQuarterly
Mar 2018
-
$0.00(0.0%)
Dec 2017
$0.00(-100.0%)
$0.00(0.0%)
Sept 2017
-
$0.00(-100.0%)
June 2017
-
$140.00 K(-76.1%)
Mar 2017
-
$585.00 K(-42.8%)
Dec 2016
$1.02 M(-62.0%)
$1.02 M(-29.6%)
Sept 2016
-
$1.45 M(-22.4%)
June 2016
-
$1.87 M(-18.0%)
Mar 2016
-
$2.28 M(-15.1%)
Dec 2015
$2.69 M(-36.5%)
$2.69 M(-12.8%)
Sept 2015
-
$3.08 M(-11.2%)
June 2015
-
$3.47 M(-9.9%)
Mar 2015
-
$3.85 M(-8.9%)
Dec 2014
$4.23 M(>+9900.0%)
$4.23 M(-9.5%)
Sept 2014
-
$4.68 M(-5.0%)
June 2014
-
$4.92 M(>+9900.0%)
Mar 2014
-
$0.00(0.0%)
Dec 2013
$0.00(-100.0%)
$0.00(0.0%)
Sept 2013
-
$0.00(0.0%)
June 2013
-
$0.00(0.0%)
Mar 2013
-
$0.00(-100.0%)
Dec 2012
$7.53 M(+9.2%)
$7.53 M
Dec 2011
$6.90 M(-10.8%)
-
Dec 2002
$7.73 M(+41.0%)
-
Dec 2001
$5.48 M(+81.1%)
-
Dec 2000
$3.03 M(+32.5%)
-
Dec 1999
$2.28 M
-

FAQ

  • What is Esperion Therapeutics annual total long term liabilities?
  • What is the all time high annual total long term liabilities for Esperion Therapeutics?
  • What is Esperion Therapeutics annual total long term liabilities year-on-year change?
  • What is Esperion Therapeutics quarterly total long term liabilities?
  • What is the all time high quarterly long term liabilities for Esperion Therapeutics?
  • What is Esperion Therapeutics quarterly long term liabilities year-on-year change?

What is Esperion Therapeutics annual total long term liabilities?

The current annual total long term liabilities of ESPR is $504.57 M

What is the all time high annual total long term liabilities for Esperion Therapeutics?

Esperion Therapeutics all-time high annual total long term liabilities is $505.18 M

What is Esperion Therapeutics annual total long term liabilities year-on-year change?

Over the past year, ESPR annual total long term liabilities has changed by +$25.16 M (+5.25%)

What is Esperion Therapeutics quarterly total long term liabilities?

The current quarterly long term liabilities of ESPR is $518.45 M

What is the all time high quarterly long term liabilities for Esperion Therapeutics?

Esperion Therapeutics all-time high quarterly total long term liabilities is $524.58 M

What is Esperion Therapeutics quarterly long term liabilities year-on-year change?

Over the past year, ESPR quarterly total long term liabilities has changed by +$24.85 M (+5.03%)